Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

Inscription Capital LLC bought a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 21,819 shares of the company's stock, valued at approximately $303,000.

Other hedge funds have also added to or reduced their stakes in the company. QRG Capital Management Inc. grew its holdings in Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Takeda Pharmaceutical by 48.6% in the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after acquiring an additional 14,831 shares during the period. US Bancorp DE grew its stake in shares of Takeda Pharmaceutical by 21.2% in the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after acquiring an additional 21,744 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Takeda Pharmaceutical by 60.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after acquiring an additional 68,200 shares during the period. Finally, Cetera Investment Advisers raised its stake in Takeda Pharmaceutical by 14.7% in the 4th quarter. Cetera Investment Advisers now owns 59,273 shares of the company's stock worth $785,000 after purchasing an additional 7,574 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.1%

Shares of NYSE:TAK opened at $14.91 on Thursday. The company has a market capitalization of $47.43 billion, a P/E ratio of 67.75 and a beta of 0.23. Takeda Pharmaceutical Co. has a 1 year low of $12.58 and a 1 year high of $15.43. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.01 and a quick ratio of 0.52. The business's 50 day simple moving average is $14.75 and its 200 day simple moving average is $14.19.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. On average, research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.